SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (820)3/21/1998 10:32:00 PM
From: Biomaven  Read Replies (1) of 1826
 
V1,

I agree that Dura is not a perfect analogy. I cited them to illustrate what it takes to _sell_ to a target group of prescribers that is probably smaller than that for Sjogren's. Convincing doctors to prescribe Salagen is more of an education process than a hard sell, but I just don't see how MGI can do even that effectively with a 20 person sales force.

I agree that no big pharm would be interested just for head & neck, but Sjogren's might just be large enough to interest one. The question is whether a 90% margin in what is likely to be a much smaller and slower to penetrate market is better than a lower margin in a much bigger market. All I am asking is that they at least seriously explore the possibility of a marketing partner, whether big pharm or CRO.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News